Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 17 | 2018 | 706 | 2.410 |
Why?
|
| HIV Infections | 17 | 2018 | 2303 | 1.330 |
Why?
|
| Endogenous Retroviruses | 5 | 2011 | 16 | 1.260 |
Why?
|
| Genotype | 8 | 2018 | 730 | 1.100 |
Why?
|
| RNA, Viral | 11 | 2011 | 301 | 0.910 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2010 | 75 | 0.640 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2007 | 221 | 0.600 |
Why?
|
| Viral Load | 11 | 2013 | 312 | 0.590 |
Why?
|
| Genetic Variation | 2 | 2015 | 387 | 0.550 |
Why?
|
| Cytomegalovirus | 2 | 2013 | 40 | 0.530 |
Why?
|
| Evolution, Molecular | 2 | 2015 | 268 | 0.510 |
Why?
|
| Seminal Vesicle Secretory Proteins | 1 | 2013 | 7 | 0.460 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 23 | 0.450 |
Why?
|
| Semen | 1 | 2013 | 51 | 0.450 |
Why?
|
| Drug Resistance, Viral | 5 | 2018 | 63 | 0.380 |
Why?
|
| Parkinsonian Disorders | 1 | 2010 | 37 | 0.370 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 88 | 0.360 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 623 | 0.340 |
Why?
|
| Xylazine | 1 | 2008 | 2 | 0.320 |
Why?
|
| Needle Sharing | 1 | 2008 | 8 | 0.320 |
Why?
|
| Syringes | 1 | 2008 | 6 | 0.320 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2008 | 34 | 0.320 |
Why?
|
| Rhodamine 123 | 1 | 2008 | 3 | 0.310 |
Why?
|
| Humans | 32 | 2020 | 37093 | 0.310 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 23 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 474 | 0.300 |
Why?
|
| HIV | 1 | 2008 | 98 | 0.300 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2008 | 121 | 0.290 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 181 | 0.290 |
Why?
|
| Virus Replication | 4 | 2013 | 278 | 0.280 |
Why?
|
| Parkinson Disease | 1 | 2007 | 178 | 0.270 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 357 | 0.250 |
Why?
|
| Adult | 13 | 2020 | 11712 | 0.240 |
Why?
|
| Hepatitis C | 3 | 2014 | 125 | 0.230 |
Why?
|
| Gene Expression | 1 | 2007 | 674 | 0.230 |
Why?
|
| Puerto Rico | 5 | 2018 | 1378 | 0.210 |
Why?
|
| Hepacivirus | 3 | 2010 | 62 | 0.210 |
Why?
|
| Flow Cytometry | 3 | 2008 | 399 | 0.200 |
Why?
|
| Saliva | 2 | 2020 | 107 | 0.190 |
Why?
|
| Child, Preschool | 2 | 2015 | 1418 | 0.190 |
Why?
|
| Young Adult | 6 | 2020 | 4268 | 0.170 |
Why?
|
| Executive Function | 1 | 2020 | 49 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2018 | 234 | 0.170 |
Why?
|
| Molecular Epidemiology | 2 | 2018 | 50 | 0.170 |
Why?
|
| Male | 14 | 2020 | 20025 | 0.170 |
Why?
|
| Middle Aged | 9 | 2020 | 10129 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2010 | 117 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2009 | 259 | 0.160 |
Why?
|
| HIV Reverse Transcriptase | 3 | 2015 | 33 | 0.160 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 1568 | 0.160 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 1 | 0.150 |
Why?
|
| Child | 2 | 2015 | 3131 | 0.150 |
Why?
|
| Seizures | 1 | 2017 | 68 | 0.140 |
Why?
|
| Female | 12 | 2020 | 20969 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2020 | 309 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2017 | 120 | 0.130 |
Why?
|
| Dominican Republic | 1 | 2015 | 20 | 0.130 |
Why?
|
| Bacteria | 1 | 2018 | 255 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 519 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2008 | 513 | 0.130 |
Why?
|
| Inflammation | 1 | 2020 | 618 | 0.130 |
Why?
|
| Interleukins | 1 | 2014 | 29 | 0.130 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 420 | 0.120 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2005 | 57 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2008 | 215 | 0.120 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 19 | 0.120 |
Why?
|
| Adolescent | 3 | 2018 | 5363 | 0.120 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 61 | 0.110 |
Why?
|
| Virus Internalization | 1 | 2013 | 28 | 0.110 |
Why?
|
| Depression | 1 | 2020 | 712 | 0.110 |
Why?
|
| Aged | 4 | 2018 | 6741 | 0.110 |
Why?
|
| Mutation | 4 | 2018 | 1095 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2010 | 304 | 0.100 |
Why?
|
| Viral Tropism | 1 | 2010 | 2 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2010 | 43 | 0.090 |
Why?
|
| Vaccines, Synthetic | 1 | 2010 | 72 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 767 | 0.090 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2009 | 5 | 0.080 |
Why?
|
| Genes, Immediate-Early | 1 | 2009 | 8 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 57 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2009 | 55 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2010 | 262 | 0.080 |
Why?
|
| Substance Abuse Detection | 1 | 2008 | 30 | 0.080 |
Why?
|
| Verapamil | 1 | 2008 | 7 | 0.080 |
Why?
|
| Saquinavir | 1 | 2008 | 3 | 0.080 |
Why?
|
| Simian immunodeficiency virus | 2 | 2005 | 59 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2009 | 110 | 0.080 |
Why?
|
| Ritonavir | 1 | 2008 | 14 | 0.080 |
Why?
|
| Vagina | 2 | 2005 | 81 | 0.080 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 81 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 56 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2007 | 64 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 186 | 0.070 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 85 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 213 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 562 | 0.070 |
Why?
|
| Ionophores | 1 | 2007 | 12 | 0.070 |
Why?
|
| Ionomycin | 1 | 2007 | 10 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2009 | 1518 | 0.070 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2006 | 3 | 0.070 |
Why?
|
| Immunization Schedule | 1 | 2006 | 7 | 0.070 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2006 | 3 | 0.070 |
Why?
|
| Astrocytoma | 1 | 2007 | 14 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 41 | 0.070 |
Why?
|
| HIV Seronegativity | 1 | 2007 | 39 | 0.070 |
Why?
|
| Diamines | 1 | 2006 | 7 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2008 | 339 | 0.070 |
Why?
|
| Benzothiazoles | 1 | 2006 | 21 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 290 | 0.070 |
Why?
|
| Organic Chemicals | 1 | 2006 | 35 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2006 | 105 | 0.070 |
Why?
|
| Fluorescence | 1 | 2006 | 121 | 0.070 |
Why?
|
| Kinetics | 1 | 2007 | 708 | 0.070 |
Why?
|
| Retroviruses, Simian | 1 | 2005 | 3 | 0.070 |
Why?
|
| Quinolines | 1 | 2006 | 64 | 0.070 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 325 | 0.070 |
Why?
|
| Mice | 2 | 2013 | 5913 | 0.060 |
Why?
|
| HIV Seropositivity | 1 | 2007 | 190 | 0.060 |
Why?
|
| Morphine Dependence | 1 | 2004 | 25 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 550 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2008 | 451 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 189 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 1 | 2004 | 10 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 885 | 0.060 |
Why?
|
| Immunodominant Epitopes | 1 | 2004 | 27 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 74 | 0.060 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 82 | 0.060 |
Why?
|
| Base Sequence | 1 | 2006 | 997 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2007 | 1369 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 935 | 0.050 |
Why?
|
| Animals | 4 | 2013 | 15081 | 0.050 |
Why?
|
| Alcoholism | 1 | 2005 | 240 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2379 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 730 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2231 | 0.040 |
Why?
|
| Phylogeny | 3 | 2011 | 644 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 41 | 0.040 |
Why?
|
| Alcohol-Related Disorders | 1 | 2020 | 55 | 0.040 |
Why?
|
| Mouth | 1 | 2018 | 45 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 171 | 0.040 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2017 | 4 | 0.040 |
Why?
|
| Japan | 1 | 2017 | 305 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 448 | 0.030 |
Why?
|
| Genes, pol | 2 | 2005 | 15 | 0.030 |
Why?
|
| Ribavirin | 1 | 2014 | 18 | 0.030 |
Why?
|
| HIV Protease | 2 | 2005 | 21 | 0.030 |
Why?
|
| Interferons | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 602 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2005 | 128 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 84 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 195 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 922 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 321 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1455 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2014 | 157 | 0.030 |
Why?
|
| Jamaica | 1 | 2013 | 11 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 515 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1015 | 0.030 |
Why?
|
| Registries | 1 | 2014 | 335 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 1180 | 0.030 |
Why?
|
| Reverse Transcription | 1 | 2011 | 18 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 93 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 628 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 2026 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2011 | 109 | 0.020 |
Why?
|
| Antigenic Variation | 1 | 2010 | 9 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 2010 | 16 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1067 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 39 | 0.020 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2010 | 45 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2009 | 12 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 19 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 79 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 63 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 108 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2009 | 29 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2009 | 40 | 0.020 |
Why?
|
| RNA Precursors | 1 | 2009 | 27 | 0.020 |
Why?
|
| India | 1 | 2009 | 88 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 172 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 661 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3562 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 173 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 400 | 0.020 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2006 | 11 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 515 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 68 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 307 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2005 | 30 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 972 | 0.020 |
Why?
|
| Cell Line | 1 | 2009 | 1354 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2004 | 18 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2721 | 0.020 |
Why?
|
| Blood | 1 | 2004 | 37 | 0.020 |
Why?
|
| Narcotics | 1 | 2004 | 32 | 0.020 |
Why?
|
| Candidiasis, Oral | 1 | 2004 | 23 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 159 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 41 | 0.020 |
Why?
|
| Viral Core Proteins | 1 | 2004 | 10 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 269 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2004 | 63 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2004 | 265 | 0.010 |
Why?
|
| Morphine | 1 | 2004 | 85 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 132 | 0.010 |
Why?
|
| Epitopes | 1 | 2004 | 148 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2003 | 12 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 54 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2003 | 26 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 1046 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 448 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 320 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1742 | 0.010 |
Why?
|